Trial Profile
A pilot study of interferon-alpha-2B dose reduction with dose optimization
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 31 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Oct 2018 Status changed from active, no longer recruiting to completed.
- 02 Jun 2015 Results (10 MU/m2 and 4 MU/m2 dosing levels) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.